FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2320777742> ?p ?o ?g. }

• W2320777742 endingPage "4149" @default.
• W2320777742 startingPage "4133" @default.
• W2320777742 abstract "In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine field seek to substantiate and extend the results by evaluating other poxvirus vectors and combinations with DNA and protein vaccines. Earlier clinical trials (EuroVacc trials 01 to 03) evaluated the immunogenicity of HIV-1 clade C GagPolNef and gp120 antigens delivered via the poxviral vector NYVAC. These showed that a vaccination regimen including DNA-C priming prior to a NYVAC-C boost considerably enhanced vaccine-elicited immune responses compared to those with NYVAC-C alone. Moreover, responses were improved by using three as opposed to two DNA-C primes. In the present study, we assessed in nonhuman primates whether such vaccination regimens can be streamlined further by using fewer and accelerated immunizations and employing a novel generation of improved DNA-C and NYVAC-C vaccine candidates designed for higher expression levels and more balanced immune responses. Three different DNA-C prime/NYVAC-C+ protein boost vaccination regimens were tested in rhesus macaques. All regimens elicited vigorous and well-balanced CD8(+)and CD4(+)T cell responses that were broad and polyfunctional. Very high IgG binding titers, substantial antibody-dependent cellular cytotoxicity (ADCC), and modest antibody-dependent cell-mediated virus inhibition (ADCVI), but very low neutralization activity, were measured after the final immunizations. Overall, immune responses elicited in all three groups were very similar and of greater magnitude, breadth, and quality than those of earlier EuroVacc vaccines. In conclusion, these findings indicate that vaccination schemes can be simplified by using improved antigens and regimens. This may offer a more practical and affordable means to elicit potentially protective immune responses upon vaccination, especially in resource-constrained settings.Within the EuroVacc clinical trials, we previously assessed the immunogenicity of HIV clade C antigens delivered in a DNA prime/NYVAC boost regimen. The trials showed that the DNA prime crucially improved the responses, and three DNA primes with a NYVAC boost appeared to be optimal. Nevertheless, T cell responses were primarily directed toward Env, and humoral responses were modest. The aim of this study was to assess improved antigens for the capacity to elicit more potent and balanced responses in rhesus macaques, even with various simpler immunization regimens. Our results showed that the novel antigens in fact elicited larger numbers of T cells with a polyfunctional profile and a good Env-GagPolNef balance, as well as high-titer and Fc-functional antibody responses. Finally, comparison of the different schedules indicates that a simpler regimen of only two DNA primes and one NYVAC boost in combination with protein may be very efficient, thus showing that the novel antigens allow for easier immunization protocols." @default.
• W2320777742 created "2016-06-24" @default.
• W2320777742 creator A5004036928 @default.
• W2320777742 creator A5005260406 @default.
• W2320777742 creator A5005741024 @default.
• W2320777742 creator A5007165900 @default.
• W2320777742 creator A5009066015 @default.
• W2320777742 creator A5015694456 @default.
• W2320777742 creator A5020871813 @default.
• W2320777742 creator A5023133097 @default.
• W2320777742 creator A5030712042 @default.
• W2320777742 creator A5034536696 @default.
• W2320777742 creator A5035514999 @default.
• W2320777742 creator A5038015992 @default.
• W2320777742 creator A5042123287 @default.
• W2320777742 creator A5042447717 @default.
• W2320777742 creator A5045011745 @default.
• W2320777742 creator A5049125429 @default.
• W2320777742 creator A5050612131 @default.
• W2320777742 creator A5054248259 @default.
• W2320777742 creator A5055025991 @default.
• W2320777742 creator A5056602559 @default.
• W2320777742 creator A5063598326 @default.
• W2320777742 creator A5067946960 @default.
• W2320777742 creator A5071488221 @default.
• W2320777742 creator A5073120779 @default.
• W2320777742 creator A5075620643 @default.
• W2320777742 creator A5077047153 @default.
• W2320777742 creator A5078873585 @default.
• W2320777742 creator A5080175927 @default.
• W2320777742 creator A5083111072 @default.
• W2320777742 creator A5084834429 @default.
• W2320777742 creator A5085028280 @default.
• W2320777742 creator A5090939942 @default.
• W2320777742 date "2016-04-15" @default.
• W2320777742 modified "2023-10-12" @default.
• W2320777742 title "Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens" @default.
• W2320777742 cites W1760248554 @default.
• W2320777742 cites W1838210676 @default.
• W2320777742 cites W1970020409 @default.
• W2320777742 cites W1970267929 @default.
• W2320777742 cites W1970593216 @default.
• W2320777742 cites W1974096769 @default.
• W2320777742 cites W1977795608 @default.
• W2320777742 cites W1980696330 @default.
• W2320777742 cites W1991518158 @default.
• W2320777742 cites W1992045336 @default.
• W2320777742 cites W1994195272 @default.
• W2320777742 cites W1996720451 @default.
• W2320777742 cites W2002722342 @default.
• W2320777742 cites W2005000140 @default.
• W2320777742 cites W2008612546 @default.
• W2320777742 cites W2011010911 @default.
• W2320777742 cites W2011670684 @default.
• W2320777742 cites W2031325112 @default.
• W2320777742 cites W2031420717 @default.
• W2320777742 cites W2031668026 @default.
• W2320777742 cites W2032640750 @default.
• W2320777742 cites W2034863440 @default.
• W2320777742 cites W2036297695 @default.
• W2320777742 cites W2044254174 @default.
• W2320777742 cites W2046201973 @default.
• W2320777742 cites W2047198040 @default.
• W2320777742 cites W2052937459 @default.
• W2320777742 cites W2053035745 @default.
• W2320777742 cites W2059474578 @default.
• W2320777742 cites W2060880470 @default.
• W2320777742 cites W2064251543 @default.
• W2320777742 cites W2070701468 @default.
• W2320777742 cites W2075345074 @default.
• W2320777742 cites W2076195337 @default.
• W2320777742 cites W2076335381 @default.
• W2320777742 cites W2082317854 @default.
• W2320777742 cites W2083002978 @default.
• W2320777742 cites W2083008217 @default.
• W2320777742 cites W2087090401 @default.
• W2320777742 cites W2089471930 @default.
• W2320777742 cites W2091180379 @default.
• W2320777742 cites W2093645417 @default.
• W2320777742 cites W2097771941 @default.
• W2320777742 cites W2102900953 @default.
• W2320777742 cites W2104784743 @default.
• W2320777742 cites W2108823547 @default.
• W2320777742 cites W2108868448 @default.
• W2320777742 cites W2109912655 @default.
• W2320777742 cites W2113826680 @default.
• W2320777742 cites W2114273761 @default.
• W2320777742 cites W2122210861 @default.
• W2320777742 cites W2131332541 @default.
• W2320777742 cites W2141669350 @default.
• W2320777742 cites W2142405752 @default.
• W2320777742 cites W2143421242 @default.
• W2320777742 cites W2146962869 @default.
• W2320777742 cites W2148029978 @default.
• W2320777742 cites W2151658023 @default.
• W2320777742 cites W2152048324 @default.
• W2320777742 cites W2152640863 @default.
• W2320777742 cites W2153163225 @default.

• next